The MDS Beacon In this column, we answer those questions so that patients can better understand how these drugs are used to treat myelodysplastic syndromes (MDS) and what decisions patients and doctors may need to make when treating MDS with one of these two agents ...
The Australian "The stem cells respond by secreting anti-inflammatory factors and growth factors ," he says. "There have been many studies indicating that adult stem cells alter their response depending on the injury type and location." His company, Regeneus, is one ... and more »
PharmaLive (press release) (subscription) These therapeutic candidates, which target the Fibroblast Growth Factor 21 (FGF-21) protein for the potential treatment of ty...
Science World Report ... scientists have not been able to direct nanotherapies to consistently differentiate cancer cells from healthy ones. Other limiting factors include high costs, too-small amounts of drugs delivered, and potential toxic side effects. ... "Our study ...
MedPage Today There are seven drugs approved to treat advanced renal cell carcinoma that inhibit vascular endothelial growth factor or its receptor like tivozanib does. All but one approval was based on improvement in progression-free survival. Thursday's lone ... and more »
Medical Daily The drug's target is all vascular endothelial growth factor (VEGF) receptors. Globally, it is estimated that more than 250,000 people are diagnosed and...
The Australian The company cited "clear scientific and medical evidence" the drug did not increase the body's production of the muscle-building hormone, insulin-like Growth Factor 1. Professor Wittert questioned what Essendon players had hoped to gain. "There is no ... and more »
HealthCanal.com Cediranib is a drug that inhibits a class of proteins called vascular endothelial growth factor receptors which regulate blood vessel formation. The drug , developed by AstraZeneca, Wilmington, Del., has been tested in clinical trials against other ...
The Australian Exasperated, Calzada's subsidiary Metabolic last week stressed its tests provided "clear scientific evidence" AOD-9604 was not an insulin growth factor or a catalyst for muscle or cartilage growth . In other words, it's not performance-enhancing even if ... and more »
Seeking Alpha One of the most concerning has been the potential ability of these compounds to upregulate VEGF (vascular endothelial growth factor ), which may have potential adverse effects on enhancing tumor growth . Thus, the omnipresent nature of this new ... In ...
